Ocugen (OCGN) News
NASDAQ: OCGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
0.7679+0.0351 (+4.79%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OCGN news summary
We found 7 recent headlines mentioning Ocugen (OCGN): 0 in the past week and 5 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, OCGN is up 4.79% at $0.7679. The most recent story, "Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN", was published by GlobeNewswire on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Ocugen headlines
- Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEANMALVERN, Pa. and SYDNEY, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, and…GlobeNewswire
- Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock RisesOCGN's Q3 revenues beat estimates. Shares surge 17.4%. Advancing gene therapy programs target three BLA submissions by 2028.NasdaqOCGN, TGTX, TARS
- Ocugen (OCGN) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Ocugen Provides Business Update with Third Quarter 2026 Financial ResultsConference Call and Webcast Today at 8:30 a.m. ETGlobeNewswire
- Ocugen to Participate in Upcoming November Investor and Industry ConferencesMALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today…GlobeNewswire
- Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a…GlobeNewswire
- Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaMALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced…GlobeNewswire